Kelun-Biotech reported a rise in first-half profit for 2026 as its revenue mix shifted toward proprietary drug sales, according to an earnings call transcript.
The biotech company attributed the improved profitability to a strategic pivot in its sales strategy, emphasizing higher-margin pharmaceutical products over earlier revenue streams. While specific financial figures were not disclosed in the transcript, management highlighted progress in pipeline development and commercialization efforts.
During the call, executives outlined plans to expand the company’s drug portfolio, focusing on late-stage clinical candidates and commercial partnerships. The shift in revenue composition reflects a broader industry trend toward specialized therapeutics, particularly in oncology and rare diseases.
Analysts monitoring the sector noted that Kelun-Biotech’s transition aligns with investor expectations for biotech firms to prioritize profitable, high-growth drug portfolios. The company’s strategy underscores the competitive pressures in the biopharmaceutical space, where revenue diversification and margin management are critical to sustaining long-term growth.
Kelun-Biotech did not provide updated guidance for the full year in the transcript. Further details on revenue breakdown and profitability metrics are expected to be included in the company’s interim financial report.
